HIPAA and Human Subjects Research: A Question & Answer Reference GuideBarnett Educational ServicesMarch 1, 2003 139 Pages - SKU: BNT2406795 |
| (March 2003)This publication, HIPAA and Human Subjects Research: A Question & Answer Reference Guide (March 2003), by Mark Barnes and Jennifer Kulynych of Ropes & Gray, quickly and conveniently access all of the essential clinical trial-related HIPAA regulations and guidance documents - and analysis and perspectives from the two leading HIPAA experts - all in one pocket-sized handbook! Learn how HIPAA will affect all aspects of clinical research --patient recruitment, informed consent, IRB reviews, clinical data handling, and the responsibilities of sponsors, IRBs, monitors, and investigators-- in this definitive reference guide designed and developed by the top HIPAA experts! This essential guide is more than just your personal HIPAA Privacy Rule library: We've supplemented all the key HIPAA privacy-related documents by having our experts answer over 100 of the most common, emerging, and difficult-to-answer HIPAA-related questions now facing clinical trial sponsors, study monitors, clinical investigators and site staff, IRBs, and others affected by the HIPAA Privacy Rule. Please note: The delivery of this report requires Adobe 6 or higher, and the ability to install right management plugin for Adobe. |
Related Markets
Research & Development Reports
- Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
- Oral Drug Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth
- Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
- Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
- Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
